Table 3.

Analyses of predictors of PFS in the training cohort. PFS progression-free survival, HR hazard ratio, CI confidence interval.

	Univariable analysis			Multivariable analysis
	HR	95%CI	P-value	HR	95%CI	P-value
Age
≥60	1			1
<60	0.75	0.58–0.98	0.037	0.69	0.52–0.91	0.01
Gender
Male	1			1
Female	1.29	0.94–1.77	0.114	1.39	0.94–2.06	0.095
ECOG-PS
0	1			1
1	1.45	1.11–1.90	0.007	1.38	1.03–1.83	0.028
Smoking status
Never	1			1
Former	0.76	0.54–1.08	0.083	0.86	0.61–1.11	0.326
Active	0.85	0.65–1.11	0.242	1.08	0.78–1.51	0.641
Location
Right	1			1
Left	0.9	0.69–1.17	0.414	0.9	0.68–1.18	0.434
Pathologic subtype
Uncommon pathological subtype	1			1
Common pathological subtype	0.67	0.46–0.98	0.038	0.59	0.40–0.87	0.009
Stage
Stage III	1			1
Stage IV	2.68	1.63–4.42	＜0.001	2.72	1.63–4.55	＜0.001
PDL1:TPS
<1%	1			1
1–49%	0.57	0.39–0.83	0.003	0.64	0.44–0.94	0.023
≥50%	0.38	0.25–0.57	＜0.001	0.45	0.30–0.68	＜0.001
Unknown	0.49	0.34–0.71	＜0.001	0.55	0.37–0.81	0.003
Line of treatments
1st	1			1
2nd	1.4	1.04–1.89	0.025	1.1	0.80–1.50	0.57
≥3rd	1.47	1.01–2.14	0.044	1.27	0.86–1.87	0.236
Treatment
Monotherapy	1			1
Combination	0.77	0.59–1.01	0.064	0.8	0.60–1.06	0.124